Vaccines in development for COVID-19
May 5, 2020…e may become available in early 2021. For a recent review see Amanat et al. Immunity 2020;52; epublished April 14, 2020. Free full text at www.cell.com/immunity/pdf/S1074-7613(20)30120-5.pdf….
Results for: C-THR81-2405 PDF Questions with A Guaranteed Success 2024 ⚒ Easily obtain free download of “ C-THR81-2405 ” by searching on ⏩ www.pdfvce.com ⏪ 🤛Exam C-THR81-2405 Format
AAN 2020 DAILY REPORT – WEDNESDAY, APRIL 29 EDITION
April 29, 2020…lowest for teriflunomide and glatiramer acetate. Zoster infection was more common in older individuals but about 25% of reports were in patients younger than 40 years. Ponesimod – new trial data: OPTIMUM is the phase III trial comparing ponesimod, a sphingosine-1 receptor modulator in development, with teriflunomide in RMS for 108 weeks (n=1131). Ponesimod was administered over a 14-day titration period to minimize the need for first-dose observat…
Slide deck: COVID-19 – Epidemiology in Canada (April 21, 2020)
April 21, 2020…Summary of epidemiology, testing and mortality rate; Canada and world statistics. Download COVID-19 slide deck…
Slide deck: COVID-19 – Epidemiology in Canada (April 14, 2020)
April 14, 2020…Summary of epidemiology, testing and mortality rate; Canada and world statistics. Download COVID-19 slide deck…
COVID-19 – FDA approves hydroxychloroquine amid controversy
April 9, 2020…microb Agents 2020 ; epublished March 20, 2020 ; free full text at https://www.sciencedirect.com/science/article/pii/S0924857920300996/pdfft?md5=332491a1ab112f0e0058fb400a5ea8ca&pid=1-s2.0-S0924857920300996-main.pdf). There was a significant difference in nasopharyngeal viral load beginning on Day 3 and continuing to Day 6. At Day 6, the virological cure rate was 100% with hydroxychloroquine/azithromycin, 57% with hydroxychloroquine monotherapy an…